Browse News
Filter News
Found 808,172 articles
-
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
4/16/2024
Innovent Biologics, Inc. announces the appointment of Dr. Nageatte Ibrahim, a world-famous Oncology Clinical Development Leader in the Pharmaceutical Industry, as the Oncology CMO.
-
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
4/16/2024
argenx SE announced that data from its Phase 3 ADHERE trial evaluating VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy were presented for the first time to the medical community during the Clinical Trials Plenary Session at the American Academy of Neurology Annual Meeting in Denver, CO.
-
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
4/16/2024
Boehringer Ingelheim announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
-
Spago Nanomedical Strengthens Management with Head of CMC & Supply
4/16/2024
Spago Nanomedical Spago Nanomedical AB announced the appointment of Birgitta Rembratt Svensson as Head of CMC & Supply.
-
CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer
4/16/2024
CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, announced that its UCLA research team has created a promising new drug candidate for treating recurrent Ewing sarcoma, a deadly children’s cancer.
-
Beckman Coulter's DxI 9000 Immunoassay Analyzer Extends Menu with New CE-Marked Hepatitis Assays at ESCMID Global
4/16/2024
Beckman Coulter Diagnostics, a leader in clinical diagnostics, announced , ahead of the congress of the European Society of Clinical Microbiology and Infectious Diseases, that it has extended the menu of DxI 9000 Immunoassay Analyzer* assays.
-
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
4/16/2024
Nxera Pharma Co., Ltd. has been notified by its partner Neurocrine Biosciences Inc. that NBI-1117568, an oral selective muscarinic M4 receptor agonist being advanced in Phase 2 clinical trials by Neurocrine for the treatment of schizophrenia and other neuropsychiatric disorders, has successfully completed a long-term preclinical toxicity program that meets US FDA requirements to allow for safe, chronic dosing in future clinical trials.
-
Faron Confirms Plans for the Coming Months Under New Leadership - April 16, 2024
4/16/2024
Faron Pharmaceuticals Ltd. announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of Dr. Juho Jalkanen as Chief Executive Officer, effective 1 May 2024.
-
IRLAB to Present at Redeye Investor Forum - April 16, 2024
4/16/2024
IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson's disease, announced that the company will present at Redeye Investor Forum on April 18.
-
Following cases of convulsions in rabbits in a preclinical study, the FDA has placed a clinical hold on Neumora Therapeutics’ Phase I schizophrenia drug candidate NMRA-266.
-
Roche said Monday that its bispecific T cell engager Columvi improved survival in a Phase III lymphoma trial, clearing the drugmaker to seek a full, expanded label that could drive sales growth.
-
An FDA advisory committee on Friday agreed that using minimal residual disease could be a viable surrogate endpoint for accelerated approval for drug development in multiple myeloma.
-
AbbVie’s small molecule drug Qulipta has durable benefits and can reduce migraine frequency through 48 weeks of follow-up, according to interim Phase III data released on Friday.
-
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
-
Roche’s Genentech subsidiary is terminating for undisclosed reasons its 2021 contract with Adaptimmune for the development of allogeneic T-cell therapeutics.
-
While the VC fund launched on Monday by Regeneron Pharmaceuticals has an investment mandate that includes healthcare broadly, Regeneron Ventures will lean towards biotechnology, devices, tools and enabling technologies.
-
GLP-1 treatments are all the rage in this space, but they aren’t the only approach in development. The pipeline assets highlighted here offer a differentiated approach, potentially increasing efficacy or reducing side effects.
-
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
-
Metabolic dysfunction-associated steatohepatitis experts welcomed Madrigal’s Rezdiffra as an “important first," but there are more mid- to late-stage therapies showing promising results.
-
EarlyDiagnostics, Inc. Co-CEO Gregory C. Critchfield, M.D. M.S., Receives Utah Governor's Medal for Science and Technology
4/15/2024
EarlyDiagnostics is pleased to announce that Co-CEO Gregory C. Critchfield, M.D. M.S., has received the State of Utah's Governor's Medal for his numerous science and technology contributions in industry.